The repurposing of a medicine already on the market to a new indication could be an opportunity to respond rapidly to a therapeutic need not yet covered, particularly in the context of rare and neglected diseases, or health emergencies. However, at each stage, difficulties may arise that will prevent the repurposed drug from being provided to patients. Beyond fortuity or a systematic strategy to detect a useful pharmacological effect, the implementation of the preclinical and clinical stages is sometimes complicated by the difficulty of accessing the molecule and its pharmaceutical data. Furthermore, relevant clinical results will not always be sufficient to ensure that a marketing authorisation is obtained or that patients receive satisfactory care. In addition to describing these various obstacles, the round table provided an opportunity to put forward recommendations for overcoming them, in particular the creation of a public–private partnership structure with sufficient funding to be able to offer individualised support for projects up to and including the marketing application.Le texte complet de cet article est disponible en PDF.
Keywords : Repurposing, Marketing authorisation, Rare diseases, Support system, Therapeutic need
|☆|| The articles, analyses and proposals resulting from the Giens Workshops are those of the authors and do not prejudge the positions of their organisations.